Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

Eligible patients will be assigned to one of two groups: Elagolix 150 mg once daily or OCPs daily, based on physician recommendation and patient preference. Baseline demographic and clinical information will be recorded. Pain outcomes (dysmenorrhea, dyspareunia, non menstrual pain) will be assessed on the NRS at baseline, 12 weeks, and 24 weeks. Adverse events will be documented throughout.

• Elagolix (Drug): Elagolix will be administered at 150 mg once daily in this study.
• Oral Contraceptive (OC) (Drug): In this study, administered once daily in a continuous 28-day cycles for 3 months

Primary outcomes

• Pain Score (Reduction in Pain) [24 weeks]: Primary outcomes will focus on patient-reported levels of dysmenorrhea, non-menstrual pelvic pain and dyspareunia. Each primary outcome will be evaluated by using numerical pain scale (NRS), ranging from 0 (no pain) to 10 (worst pain). These pain scores are scheduled to be recorded at baseline (week 0), mid-treatment (week 12) and at end of treatment (week 24). Any adverse events occurring during this duration will also be documented.

Sex: Female, ages: 18 Years to 45 Years

Inclusion Criteria:

* Women aged 18-45 years
* clinically or surgically confirmed endometriosis
* having regular menstrual cycles
* willingness to participate with informed consent.

Exclusion Criteria

* Contraindications to OCPs (e.g., thromboembolism, cardiovascular disease, uncontrolled hypertension, smoking over age 35)
* Contraindications to Elagolix (e.g., osteoporosis, pregnancy, hypersensitivity, severe depression) Prior hysterectomy or bilateral oophorectomy, Other identifiable causes of pelvic pain.